IP Group plc
IP Group plc
Our global sites
IP Group case study on Pfizer drug royalty interest

HealthTech

Featured

From UK science to global scale: IP Group’s role in Pfizer’s obesity drug programme

The value crystallising across IP Group’s portfolio is often the result of decades of foundational science.

Read case study

IP Group insight on its role in Pfizer’s obesity drug programme
  • HealthTech

From UK science to global scale: IP Group’s role in Pfizer’s obesity drug programme
IP Group insight on Intelligent Ultrasound
  • HealthTech

Intelligent Ultrasound: AI for Safer, Smarter Scanning
  • HealthTech

Spotlighting: Genomics

Dr Lee Thornton discussing IP Group portfolio company Intrinsic
  • DeepTech

Spotlighting: Intrinsic

Mike Molinari of IP Group Australia talking about portfolio company Hysata
  • CleanTech

Spotlighting: Hysata

IP Group insight on Mixergy
  • CleanTech

Mixergy: The forefront of smart hot water solutions and grid optimisation

IP Group insight on sale of Garrison to Everfox
  • DeepTech

Substantial return from hardsec pioneer Garrison
Image of woman with phone for IP Group Case Study on Featurespace exit
  • DeepTech

Featurespace: Our Largest Exit to Date
  • DeepTech

How WaveOptics became one of the biggest ever exits for a venture-backed “deeptech” start-up in Europe
Supporting innovation
  • HealthTech

Supporting innovation through to unicorn status with Oxford Nanopore
Case study image
  • HealthTech

Helping Istesso tackle severe, chronic autoimmune disease
Case study image
  • CleanTech

Ceres powers clean energy systems and fuels exceptional returns

Showing XX of 12

Load more

Related pages

Investor

Investor relations

Our impact

Our impact